Hydroxychloroquine or chloroquine with or without macrolides is linked to in-hospital mortality and arrhythmia.
TUESDAY, May 26, 2020 (HealthDay News) -- For patients with COVID-19 requiring hospitalization, there is no evidence of benefit for use of hydroxychloroquine or chloroquine with or without a macrolide, according to a study published online May 22 in The Lancet.
Mandeep R. Mehra, M.D., from the Brigham and Women's Hospital Heart and Vascular Center in Boston, and colleagues conducted a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without macrolides for COVID-19 treatment. A total of 96,032 patients hospitalized at 671 hospitals in six continents between Dec. 20, 2019, and April 14, 2020, were included. They were classified into four treatment groups (1,868 received chloroquine; 3,783 received chloroquine with a macrolide; 3,016 received hydroxychloroquine; and 6,221 received hydroxychloroquine with a macrolide) and a control group (81,144 patients).